1-8 of 8
Suzanne Lentzsch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups

Free
Sundar Jagannath, Joshua Richter, Madhav V. Dhodapkar, James E. Hoffman, Hans C. Lee, Attaya Suvannasankha, Mansi R. Shah, Suzanne Lentzsch, Jeffrey A. Zonder, Rachid Baz, Joseph J. Maly, Swathi Namburi, Ka Lung Wu, Matthew Pianko, Rebecca Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez Lopez, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn S. Kroog, Yariv Houvras, Naresh Bumma
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT001.
https://doi.org/10.1158/1538-7445.AM2024-CT001
Published: 05 April 2024
View articletitled, Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups
Journal Articles

Abstract 3619: Post CAR-T lymphocytosis as a surrogate of BCMA CAR-T expansion, response, and prognosis in multiple myeloma

Free
Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek Mouhieddine, Josh Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, David Jayabalan, Christian Gordillo, Hei Ton Chan, Markus Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ren Reshef, Adriana Rossi, Samir Parekh, Sundar Jagannath, Shambavi Richards, Ruben Niesvizky, Mark Bustoros
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3619.
https://doi.org/10.1158/1538-7445.AM2024-3619
Published: 22 March 2024
View articletitled, Abstract 3619: Post CAR-T lymphocytosis as a surrogate of BCMA CAR-T expansion, response, and prognosis in multiple myeloma
Journal Articles

Cell-based and cytokine-directed chemical screen predicts the drug potency with anti-multiple myeloma activities

Free
Rentian Feng, Jorge Rios, Tomifumi Onishi, Adele Marrangoni, Eliser Goreli, Suzanne Lentzsch
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 1267.
Published: 01 May 2008
View articletitled, Cell-based and cytokine-directed chemical screen predicts the drug potency with anti-multiple myeloma activities
Journal Articles

Immunomodulatory derivatives of thalidomide inhibit osteoclast formation by down regulation of PU.1

Free
Gulsum Anderson, Markus Y. Mapara, David Stirling, G. David Roodman, Suzanne Lentzsch
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1092.
Published: 15 April 2006
View articletitled, Immunomodulatory derivatives of thalidomide inhibit osteoclast formation by down regulation of PU.1
Journal Articles

Mechanisms of drug resistance towards Thalidomide (Thal) and its immunomodulatory derivatives (IMiDs) in Multiple Myeloma (MM) cells: Role of C/EBPb

Free
Suzanne Lentzsch, Markus Y. Mapara, David Roodman, Martin Janz, Ralf Bargou, David Stirling
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 452.
Published: 01 May 2005
View articletitled, Mechanisms of drug resistance towards Thalidomide (Thal) and its immunomodulatory derivatives (IMiDs) in Multiple Myeloma (MM) cells: Role of C/EBPb
Journal Articles

Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model

Available to Purchase
Richard LeBlanc, Laurence P. Catley, Teru Hideshima, Suzanne Lentzsch, Constantine S. Mitsiades, Nicholas Mitsiades, Donna Neuberg, Olga Goloubeva, Christine S. Pien, Julian Adams, Deepak Gupta, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2002) 62 (17): 4996–5000.
Published: 01 September 2002
View articletitled, Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model
Open the PDF for Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model in another window
Journal Articles

The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment

Available to Purchase
Boris Lin, Klaus Podar, Deepak Gupta, Yu-Tzu Tai, Sigui Li, Edie Weller, Teru Hideshima, Suzanne Lentzsch, Faith Davies, Cheng Li, Ellen Weisberg, Robert L. Schlossman, Paul G. Richardson, James D. Griffin, Jeanette Wood, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2002) 62 (17): 5019–5026.
Published: 01 September 2002
View articletitled, The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment
Open the PDF for The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment in another window
Journal Articles

S -3-Amino-phthalimido-glutarimide Inhibits Angiogenesis and Growth of B-Cell Neoplasias in Mice

Available to Purchase
Suzanne Lentzsch, Michael S. Rogers, Richard LeBlanc, Amy E. Birsner, Jamshed H. Shah, Anthony M. Treston, Kenneth C. Anderson, Robert J. D’Amato
Journal: Cancer Research
Cancer Res (2002) 62 (8): 2300–2305.
Published: 01 April 2002
View articletitled, S -3-Amino-phthalimido-glutarimide Inhibits Angiogenesis and Growth of B-Cell Neoplasias in Mice
Open the PDF for S -3-Amino-phthalimido-glutarimide Inhibits Angiogenesis and Growth of B-Cell Neoplasias in Mice in another window